Jane Osbourn

Vice-President, Research and Development

AstraZeneca

Dr Jane Osbourn joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An expert in antibody engineering, she has authored many key publications and patents, and made a significant contribution to the discovery and development of a number of marketed drugs and more than 40 clinical candidates. She has worked across many therapy areas and currently leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies. She is Site Leader for MedImmune’s facility in Cambridge UK and chairs the cross-campus leadership team for AstraZeneca in Cambridge. In 2015 she was elected Chair of the BioIndustry Association, and she is also a Director of Babraham Bioscience Technologies and a Director of Cambridge Enterprise.